立方制药(003020.SZ)：美沙拉秦肠溶片完成药品注册

Core Viewpoint - The company, Lifan Pharmaceutical, has received approval from the National Medical Products Administration for the registration certificate of Mesalazine enteric-coated tablets, indicating a significant advancement in its product offerings [1]. Group 1: Product Approval - The approval pertains to Mesalazine, a non-steroidal anti-inflammatory drug that inhibits the synthesis of prostaglandins and the formation of inflammatory mediators such as leukotrienes, thereby significantly suppressing inflammation in the intestinal mucosa [1]. - Mesalazine enteric-coated tablets are indicated for the treatment of acute exacerbations of ulcerative colitis and for maintenance therapy to prevent recurrence, as well as for the treatment of acute exacerbations of Crohn's disease [1]. - The original developer of Mesalazine is the German company, Ferring Pharmaceuticals [1].